Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the Congo.

Choi, EMORCID logo; Kasonia, KORCID logo; Kavunga-Membo, H; Mukadi-Bamuleka, DORCID logo; Soumah, A; Mossoko, Z; Edwards, TORCID logo; Tetsa-Tata, DORCID logo; Makarimi, R; Toure, O; +19 more...Mambula, G; Brindle, H; Camacho, AORCID logo; Connor, NEORCID logo; Mukadi, PORCID logo; McLean, CORCID logo; Keshinro, BORCID logo; Gaddah, AORCID logo; Robinson, C; Luhn, K; Foster, J; Roberts, CHORCID logo; Johnson, JE; Imbault, N; Bausch, DG; Grais, RF; Watson-Jones, DORCID logo; Muyembe-Tamfum, JJ; Tujiokowe Study Consortium and (2024) Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the Congo. Vaccines, 12 (8). p. 828. ISSN 2076-393X DOI: 10.3390/vaccines12080828
Copy

During the 2018-2020 Ebola virus disease outbreak in Democratic Republic of the Congo, a phase 3 trial of the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine (DRC-EB-001) commenced in Goma, with participants being offered the two-dose regimen given 56 days apart. Suspension of trial activities in 2020 due to the COVID-19 pandemic led to some participants receiving a late dose 2 outside the planned interval. Blood samples were collected from adults, adolescents, and children prior to their delayed dose 2 vaccination and 21 days after, and tested for IgG binding antibodies against Ebola virus glycoprotein using the Filovirus Animal Nonclinical Group (FANG) ELISA. Results from 133 participants showed a median two-dose interval of 9.3 months. The pre-dose 2 antibody geometric mean concentration (GMC) was 217 ELISA Units (EU)/mL (95% CI 157; 301) in adults, 378 EU/mL (281; 510) in adolescents, and 558 EU/mL (471; 661) in children. At 21 days post-dose 2, the GMC increased to 22,194 EU/mL (16,726; 29,449) in adults, 37,896 EU/mL (29,985; 47,893) in adolescents, and 34,652 EU/mL (27,906; 43,028) in children. Participants receiving a delayed dose 2 had a higher GMC at 21 days post-dose 2 than those who received a standard 56-day regimen in other African trials, but similar to those who received the regimen with an extended interval.


picture_as_pdf
vaccines-12-00828-1.pdf
subject
Published Version
Available under Creative Commons: Attribution 4.0

View Download

Supplemental Material


Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL Data Cite XML EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads